Merck KGaA's return of TLR9 agonist rights a good deal for Idera
This article was originally published in Scrip
Executive Summary
Perceiving Merck KGaA's return to Idera Pharmaceuticals the global rights to IMO-2055, a toll-like receptor 9 (TLR9) agonist under investigation to treat various cancers, as a positive turn of events on 30 November, investors drove shares of the small Cambridge, Massachusetts biotech up as high as 24.6%.